[Federal Register Volume 68, Number 244 (Friday, December 19, 2003)]
[Notices]
[Pages 70827-70828]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-31324]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Postnatal Stem Cells and 
Uses Thereof

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
PCT application number PCT/US03/12276 filed April 19, 2003 entitled, 
``Postnatal Stem Cells and Uses Thereof'' to Dentigenix, having a place 
of business in the State of Washington. The field of use may be limited 
to the treatment of dental regeneration. The United States of America 
is the assignee of the patent rights in this invention. This 
announcement is the first notice to grant an exclusive license to this 
technology.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before February 
17, 2004 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries,

[[Page 70828]]

comments and other materials relating to the contemplated license 
should be directed to: Marlene Shinn-Astor, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 435-4426; Facsimile: (301) 402-0220; e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: This technology encompasses human postnatal 
deciduous dental pulp stem cells commonly known as ``baby teeth'', that 
are used to create dentin and have been shown to differentiate into 
cells of specialized function such as neural cells, adipocytes, and 
odontoblasts. It is believed that these cells could be manipulated to 
repair damaged teeth, induce the regeneration of bone, and treat neural 
injury or disease.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: December 12, 2003.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 03-31324 Filed 12-18-03; 8:45 am]
BILLING CODE 4140-01-P